

# Ylenia Cortolezzis

## WORK EXPERIENCE

---

### Visiting PhD student

*University of Texas at Austin* [ May 2024 – Oct 2024 ]

**Unit/Department:** Department of Molecular Biosciences, Institute for Cellular and Molecular Biology  
Kyle Miller lab., Department of Molecular Biosciences, 100 E 24th St, Austin, TX 78712, USA, Austin (United States)  
<http://www.kmmillerlab.org/>

### Internship

*Centro di Riferimento Oncologico* [ Jul 2020 – Jul 2021 ]

Via Franco Gallini, 2, 33081, Aviano (PN) (Italy)  
[www.cro.it](http://www.cro.it)

### Internship

*I.R.C.C.S. materno infantile Burlo Garofolo* [ Aug 2017 – Sep 2017 ]

Via dell'Istria 65/1, 34137, Trieste (Italy)  
[www.burlo.trieste.it](http://www.burlo.trieste.it)

## EDUCATION AND TRAINING

---

### Postdoctoral Research Fellow

*University of Udine* [ 1 Nov 2024 – Present ]

**Field of study:** Characterization of the protein complex involved in R-loop processing during oncogenesis.  
R-loop and G-quadruplex structures.  
Piazzale Massimiliano Kolbe, 4, 33100, Udine (Italy)

### PhD in Biomedical and Biotechnological Sciences

*University of Udine* [ 1 Nov 2021 – 31 Oct 2024 ]

**Field of study:** Identification of epigenetic regulators of non-canonical high-order chromatin structures during oncogenesis.  
R-loop and G-quadruplex structures.  
Piazzale Massimiliano Kolbe, 4, 33100, Udine (Italy)  
[www.uniud.it](http://www.uniud.it)

### Master's degree in Medical Biotechnology

*University of Trieste* [ 2018 – 19 Jul 2021 ]

**Field of study:** Pharmaceutical, Veterinary and Medical biotechnologies – LM-9  
**Thesis:** Role of p27kip1 in senescence induced by CDK4/6 inhibitors in breast cancer  
Piazzale Europa, 1, 34127, Trieste (Italy)

### Bachelor's degree in Biological Sciences and technologies

*University of Trieste* [ 2015 – 27 Jul 2018 ]

**Field of study:** Biotechnologies – L-2  
**Thesis:** The Silver-Russell syndrome  
Piazzale Europa, 1, 34127, Trieste (Italy)

### High School diploma

*ISIS "Magrini Marchetti"* [ 2010 – 2015 ]

**Field of study:** Opzione Scienze Applicate  
Via Praviolai 18, 33013, Gemona del Friuli (UD) (Italy)

## CONFERENCES AND SEMINARS

---

**63° SIB Congress** [ 10 Sep 2025 – 12 Sep 2025 ] - Palermo, Italy

**Cancer Genomics** [ 15 Nov 2023 – 17 Nov 2023 ] - EMBL Heidelberg, Germany

**62° SIB Congress** [ 07 Sep 2023 – 09 Sep 2023 ] - Florence, Italy

**Summer School Molecular Basis of Ageing: from mechanisms to diseases** [ 04 Sep 2023 – 06 Sep 2023 ] - Udine, Italy

**FISV 2022 Congress** [ 14 Sep 2022 – 16 Sep 2022 ] - Naples, Italy

**Creating a platform for precision anti-cancer medicine** Interreg V-A Italia-Austria 2014-2020 'PreCanMed' [ 14 Jun 2019 ] – Trieste, Italy

## PUBLICATIONS

---

- Tolotto V, Gualandi N, Colitti M, Picco R, Cortolezzis Y, D'Este F, Gani M, Hancock W W, Terroso G, Degrassi C, Brancolini C, Xodo LE, Di Giorgio E. Class IIa HDACs forced degradation allows re-sensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer (submitted).
- Cortolezzis Y, Othman Z, Agostini F, Ibrahim I, Picco R, Salgado GF, Di Giorgio E, Xodo LE. Post-transcriptional control of KRAS: functional roles of 5'UTR RNA G-quadruplexes, long noncoding RNA, and hnRNPA1. *Nucleic Acids Res.* 2025 Sep 5;53(17):gkaf886. doi: 10.1093/nar/gkaf886. PMID: 40973454; PMCID: PMC12449053.

- Azeroglu B, Khurana S, Wang SC, Tricola GM, Sharma S, Jubelin C, Cortolezzis Y, Pegoraro G, Miller KM, Stracker TH, Lazzerini Denchi E. Identification of modulators of the ALT pathway through a native FISH-based optical screen. *Cell Rep.* 2025 Jan 28;44(1):115114. doi: 10.1016/j.celrep.2024.115114. Epub 2024 Dec 26. PMID: 39729394; PMCID: PMC11844024.
- Di Giorgio E, Xodo S, Orsaria M, Mariuzzi L, Picco R, Tolotto V, Cortolezzis Y, D'Este F, Grandi N, Driul L, Londero A, Xodo LE. The central role of creatine and polyamines in fetal growth restriction. *FASEB J.* 2024 Dec 15;38(23):e70222. doi: 10.1096/fj.202401946R. PMID: 39614665; PMCID: PMC11607630. Di Giorgio E, Cortolezzis Y, Gualandi N, Agostini F, Rapozzi V, Xodo LE. NRF2 interacts with distal enhancer and inhibits nitric oxide synthase 2 expression in KRAS-driven pancreatic cancer cells. *Biochim Biophys Acta Mol Cell Res.* 2024 Jan;1871(1):119606. doi: 10.1016/j.bbamcr.2023.119606. Epub 2023 Oct 16. PMID: 37852325
- Di Giorgio E, Choudhary H, Ferino A, Cortolezzis Y, Dalla E, D'Este F, Comelli M, Rapozzi V, Xodo LE. Suppression of the KRAS-NRF2 axis shifts arginine into the phosphocreatine energy system in pancreatic cancer cells. *iScience.* 2023 Nov 24;26(12):108566. doi: 10.1016/j.isci.2023.108566. PMID: 38144458; PMCID: PMC10746371.

Udine, 22/10/2025